This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hassan, R. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Hassan, R. Articles by Pastan, I.

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Authors' Affiliations: ¹ Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and ² Clinical Center, NIH, Bethesda, Maryland; ³ Department of Medicine, University of Oklahoma, Oklahoma City, Oklahoma; ⁴ Department of Medicine, University of Chicago, Chicago, Illinois; and ⁵ Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Requests for reprints: Raffit Hassan, Laboratory of Molecular Biology, National Cancer Institute, Room 5116, 37 Convent Drive, Bethesda, MD 20892-4264. Phone: 301-451-8742; Fax: 301-402-1344; E-mail: hassanr{at}mail.nih.gov.

Purpose: To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers.

Experimental Design: SS1P given as a 30-min i.v. infusion every other day (QOD) for six or three doses was administered to 34 patients with advanced mesothelioma (n = 20), ovarian (n = 12), and pancreatic (n = 2) cancer.

Results: The initial cohort of 17 patients received SS1P QOD x 6 doses and the MTD was 18 µg/kg/dose. Dose-limiting toxicities (DLT) included grade 3 uticaria (one patient) and grade 3 vascular leak syndrome (two patients). To allow further SS1P dose escalation, 17 patients were treated on the QOD x 3 schedule and the MTD was 45 µg/kg/dose. The DLT was grade 3 pleuritis and was seen in two of two patients treated at a dose of 60 µg/kg and in one of nine patients treated at a dose of 45 µg/kg. At the MTD of 45 µg/kg, the mean C_max of SS1P was 483 ng/mL and half-life was 466 min. Of the 33 evaluable patients treated, 4 had minor responses, 19 had stable disease (including 2 with resolution of ascites), and 10 had progressive disease.

Conclusions: SS1P is well tolerated with pleuritis as the DLT at the highest dose level. Evidence of clinical activity was noted in a group of heavily pretreated patients. Phase II clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies.

This article has been cited by other articles:

				Y. Feng, X. Xiao, Z. Zhu, E. Streaker, M. Ho, I. Pastan, and D. S. Dimitrov A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity Mol. Cancer Ther., May 1, 2009; 8(5): 1113 - 1118. [Abstract] [Full Text] [PDF]

				J. E. Weldon, L. Xiang, O. Chertov, I. Margulies, R. J. Kreitman, D. J. FitzGerald, and I. Pastan A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity Blood, April 16, 2009; 113(16): 3792 - 3800. [Abstract] [Full Text] [PDF]

				C. Carpenito, M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains PNAS, March 3, 2009; 106(9): 3360 - 3365. [Abstract] [Full Text] [PDF]

				Y. Zhang and I. Pastan High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy Clin. Cancer Res., December 15, 2008; 14(24): 7981 - 7986. [Abstract] [Full Text] [PDF]

				S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., September 1, 2008; 87(1): 97 - 130. [Abstract] [Full Text] [PDF]

				M. Onda, R. Beers, L. Xiang, S. Nagata, Q.-c. Wang, and I. Pastan An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes PNAS, August 12, 2008; 105(32): 11311 - 11316. [Abstract] [Full Text] [PDF]

				Y. Tsuruta, L. Pereboeva, M. Breidenbach, D. T. Rein, M. Wang, R. D. Alvarez, G. P. Siegal, P. Dent, P. B. Fisher, and D. T. Curiel A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3582 - 3588. [Abstract] [Full Text] [PDF]

				R. Hassan, V. C. Broaddus, S. Wilson, D. J. Liewehr, and J. Zhang Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts Clin. Cancer Res., December 1, 2007; 13(23): 7166 - 7171. [Abstract] [Full Text] [PDF]

				Y. Zhang, L. Xiang, R. Hassan, and I. Pastan Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors PNAS, October 23, 2007; 104(43): 17099 - 17104. [Abstract] [Full Text] [PDF]